Marco Meglio is an Editor at Neurology Live. He focuses on medicine and healthcare, covering a range of topics including FDA regulations, diagnostics, and the healthcare system, with a particular interest in the implications of the Coronavirus pandemic. Marco's work has been featured in Cliggott Publishing Co, Contagion_Live, AJMC - The American Journal of Managed Care, CGTLive, Patient Care, NeurologyLive, NewsBreak, and HCP Live.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Marco Meglio's coverage primarily focuses on the healthcare and pharmaceutical industry, with a strong emphasis on neurology-related topics such as clinical trials, multiple sclerosis, Parkinson's disease, and Duchenne muscular dystrophy. His articles frequently cite data and press releases.
Given this focus, Marco may be interested in receiving pitches related to ongoing or upcoming clinical trials in the field of neurology and pharmaceuticals. Pitches that offer access to exclusive data or insights from leading experts within these areas would likely resonate well with him.
As he covers a wide range of scientific themes within healthcare and pharmaceuticals, sources should ensure that their pitches are evidence-based and provide valuable contributions to ongoing research or developments in these fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Isabella Ciccone, Marco Meglio, David A. Hafler
The William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine talked about refining multiple sclerosis in line with the updated diagnostic criteria. [WATCH TIME: 5 minutes]
By: John Michael Schreiber, Julie Ziobro, Marco Meglio
A duo of experts discussed the importance of addressing barriers such as provider comfort, access to genetic counselors, and insurance coverage to reduce diagnostic latency and standardize genetic testing for epilepsy. [WATCH TIME: 5 minutes]
By: Marco Meglio
The submission was based on promising data from a phase 3 and phase 2 study, where treatment with apitegromab led to significant improvements in motor function among patients with SMA on SMN-targeted treatments.
By: Isabella Ciccone, Marco Meglio
Explore some of the most highly anticipated clinical trials with data readouts expected in the second half of 2025—key updates that researchers and clinicians in neurology won't want to miss.
By: Isabella Ciccone, Marco Meglio, Igor Koralnik
The chief of neuroinfectious diseases and global neurology at Northwestern Medicine talked about a relatively new autoimmune condition, marked by mitochondrial dysfunction. [WATCH TIME: 2 minutes]
By: Marco Meglio
Significant improvements were observed in depression and patient satisfaction with fascia exercises compared to conventional physiotherapy.
By: Isabella Ciccone, Marco Meglio
A new study identified key clinical and ultrasound markers that improved the differentiation between 2 conditions with overlapping features.
By: Marco Meglio
The initial cohort of the EPISOD1 trial demonstrated no significant safety concerns for AMT-162, enabling progression to the next dose-escalation phase.
By: Isabella Ciccone, Marco Meglio
Recent results from a phase 2 trial of ATH434 revealed its potential in reducing brain iron accumulation and preserving motor function in early-stage multiple system atrophy.
By: Isabella Ciccone, Marco Meglio
Suzetrigine, a selective inhibitor of the NaV1.8 sodium channel, offers an alternative opioid treatment option for patients to treat moderate to severe pain without risk of addiction.
(833) 317-6278 
